New Clinical Advisory
by Re Mishra
The National Institute of Neurological Disorders and Stroke (NINDS) issued a new Clinical Advisory on September 19, 2011:
Secondary Prevention of Small Subcortical Strokes Trial: NINDS Stops Treatment with Combination Antiplatelet Therapy (Clopidogrel plus Aspirin) Due to Higher Risk of Major Hemorrhage and Death
NINDS has stopped the combination antiplatelet intervention in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. This was a randomized, multicenter clinical trial conducted throughout North America, Latin America and Spain, to learn about preventing a second stroke in patients who had a subcortical stroke and to learn how to prevent cognitive problems after a stroke.
New Clinical Advisory Issued by National Institute of Neurological Disorders and Stroke (NINDS). NLM Tech Bull. 2011 Sep-Oct;(382):e6.
This entry was posted
on Monday, September 19th, 2011 at 5:18 pm and is filed under General (all entries), NLM Technical Bulletin.
You can follow any responses to this entry through the RSS 2.0 feed.
Both comments and pings are currently closed.
